Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Because we are performing region-based simulations only (i.e., no vertex-wise modeling), the leadfield matrix was simplified by summing the coefficients of vertices that belong to the same region. EEG ...